RAAS Inhibitors
Cross-source consensus on RAAS Inhibitors from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Dosage & preparation
Risks & contraindications
Evidence quality
Highlighted claims
- All trial participants continue their existing ACE inhibitor or ARB dose unchanged for 28 weeks. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- RAAS inhibitors are the current standard of care for hereditary kidney diseases with proteinuria. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- RAAS inhibitors reduce proteinuria by lowering intraglomerular pressure. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- RAAS inhibitor monotherapy has limited efficacy in reducing proteinuria. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)
- RAAS inhibitor use carries risk in hypovolaemia, acute kidney injury, or hyperkalaemia. — Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD)